Applications of artificial intelligence in prostate cancer histopathology.

Journal: Urologic oncology
PMID:

Abstract

The diagnosis of prostate cancer (PCa) depends on the evaluation of core needle biopsies by trained pathologists. Artificial intelligence (AI) derived models have been created to address the challenges posed by pathologists' increasing workload, workforce shortages, and variability in histopathology assessment. These models with histopathological parameters integrated into sophisticated neural networks demonstrate remarkable ability to identify, grade, and predict outcomes for PCa. Though the fully autonomous diagnosis of PCa remains elusive, recently published data suggests that AI has begun to serve as an initial screening tool, an assistant in the form of a real-time interactive interface during histological analysis, and as a second read system to detect false negative diagnoses. Our article aims to describe recent advances and future opportunities for AI in PCa histopathology.

Authors

  • Dallin Busby
    Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Ralph Grauer
    Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Krunal Pandav
    Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York City, New York, USA.
  • Akshita Khosla
    Department of Internal Medicine, Crozer Chester Medical Center, Philadelphia, PA.
  • Parag Jain
    PathomIQ, Inc, Cupertino, CA.
  • Mani Menon
  • G Kenneth Haines
    Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Carlos Cordon-Cardo
    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Michael A Gorin
    Milton and Carroll Petrie Department of Urology Icahn School of Medicine at Mount Sinai New York New York USA.
  • Ashutosh K Tewari
    School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.